title: Advances in pediatric asthma in 2014: Moving toward a population health perspective.
abstract: Last year's "Advances in pediatric asthma in 2013: Coordinating asthma care" concluded that, "Enhanced communication systems will be necessary among parents, clinicians, health care providers and the pharmaceutical industry so that we continue the pathway of understanding the disease and developing new treatments that address the unmet needs of patients who are at risk for severe consequences of unchecked disease persistence or progression." This year's summary will focus on further advances in pediatric asthma related to prenatal and postnatal factors altering the natural history of asthma, assessment of asthma control, and new insights regarding the management of asthma in children as indicated in Journal of Allergy and Clinical Immunology publications in 2014. A major theme of this review is how new research reports can be integrated into medical communication in a population health perspective to assist clinicians in asthma management. The asthma specialist is in a unique position to convey important messages to the medical community related to factors that influence the course of asthma, methods to assess and communicate levels of control, and new targets for intervention, as well as new immunomodulators. By enhancing communication among patients, parents, primary care physicians, and specialists within provider systems, the asthma specialist can provide timely information that can help to reduce asthma morbidity and mortality.
authors: Pediatric Asthma Research Program, Section of Pediatric Pulmonary Medicine, Breathing Institute, Department of Pediatrics, Children's Hospital Colorado, and the Department of Pediatrics, University of Colorado Denver School of Medicine, Aurora, Colo. Electronic address: Stanley.Szefler@childrenscolorado.org.
authors: Stanley J
authors: SJ
authors: Szefler
mesh_terms: D000305:Adrenal Cortex Hormones / Q000627:therapeutic use; D000318:Adrenergic beta-Agonists / Q000627:therapeutic use; D018927:Anti-Asthmatic Agents / Q000627:therapeutic use*; D001249:Asthma / Q000175:diagnosis / Q000188:drug therapy* / Q000276:immunology / Q000473:pathology; D002648:Child; D019468:Disease Management; D018450:Disease Progression; D005260:Female; D006801:Humans; D006967:Hypersensitivity / Q000175:diagnosis / Q000188:drug therapy* / Q000276:immunology / Q000473:pathology; D007155:Immunologic Factors / Q000627:therapeutic use; D020024:Leukotriene Antagonists / Q000627:therapeutic use; D018802:Patient-Centered Care; D057285:Precision Medicine; D011247:Pregnancy; D011297:Prenatal Exposure Delayed Effects / Q000175:diagnosis / Q000188:drug therapy* / Q000276:immunology / Q000473:pathology
chemical_list: D000305:Adrenal Cortex Hormones; D000318:Adrenergic beta-Agonists; D018927:Anti-Asthmatic Agents; D007155:Immunologic Factors; D020024:Leukotriene Antagonists
keywords: Airway remodeling; asthma; asthma control; asthma exacerbations; biomarkers; early intervention in asthma; environment; genetics; inhaled corticosteroids; leukotriene receptor antagonists; long-acting β-adrenergic agonists; personalized medicine; severe asthma; therapeutics